We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
+0.36%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$250M
AUM Growth
+$113M
Cap. Flow
+$139M
Cap. Flow %
55.71%
Top 10 Hldgs %
70.9%
Holding
100
New
34
Increased
19
Reduced
25
Closed
17

Top Buys

1
TENX icon
Tenax Therapeutics
TENX
+$13M
2
CAMP icon
CAMP4 Therapeutics
CAMP
+$5.51M
3
VSTM icon
Verastem
VSTM
+$3.52M
4
CRIS icon
Curis
CRIS
+$3.41M
5
SLGL icon
Sol-Gel Technologies
SLGL
+$2.01M

Top Sells

1
INDV icon
Indivior Pharmaceuticals
INDV
+$3.59M
2
IKT icon
Inhibikase Therapeutics
IKT
+$2.47M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$2.39M
4
ELDN icon
Eledon Pharmaceuticals
ELDN
+$2.02M
5
EDSA icon
Edesa Biotech
EDSA
+$1.97M

Sector Composition

1 Healthcare 45.53%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IKT icon
26
Inhibikase Therapeutics
IKT
$331M
$1.61M 0.64%
957,202
-1,390,945
-59% -$2.47M
CBIO
27
Crescent Biopharma
CBIO
$407M
$1.56M 0.63%
85,000
-2,682
-3% -$30.8K
ACET icon
28
Adicet Bio
ACET
$75.9M
$1.51M 0.61%
221,955
+1,944
+0.9% +$14.6K
XFOR icon
29
X4 Pharmaceuticals
XFOR
$360M
$1.38M 0.55%
335,309
-258,264
-44% -$967K
OKYO
30
OKYO Pharma
OKYO
$75M
$1.37M 0.55%
+850,000
New +$1.65M
SIBN icon
31
CALL
SI-BONE Inc
SIBN
$771M
$1.26M 0.51%
+100,000
New +$1.56M
MNKD icon
32
CALL
MannKind Corp
MNKD
$1.25B
$1.23M 0.49%
+500,000
New +$2.23M
HRTX icon
33
Heron Therapeutics
HRTX
$89.1M
$1.12M 0.45%
1,402,191
+164,389
+13% +$190K
LUNG icon
34
Pulmonx
LUNG
$59.1M
$991K 0.4%
768,288
+281,888
+58% +$466K
INAB icon
35
IN8bio
INAB
$12.8M
$982K 0.39%
663,412
+498,519
+302% +$964K
NMRA icon
36
CALL
Neumora Therapeutics
NMRA
$298M
$975K 0.39%
+500,000
New +$1.3M
SRZN icon
37
Surrozen
SRZN
$255M
$961K 0.39%
33,005
-80,626
-71% -$1.93M
CTMX icon
38
CALL
CytomX Therapeutics
CTMX
$788M
$940K 0.38%
+200,000
New +$1.02M
CTMX icon
39
CytomX Therapeutics
CTMX
$788M
$940K 0.38%
+200,000
New +$1.02M
DCTH icon
40
CALL
Delcath Systems
DCTH
$442M
$928K 0.37%
+100,000
New +$969K
ARDX icon
41
CALL
Ardelyx
ARDX
$1.28B
$899K 0.36%
+150,000
New +$992K
PMVP icon
42
PMV Pharmaceuticals
PMVP
$71.5M
$878K 0.35%
708,102
-442,657
-38% -$563K
BIOA
43
BioAge Labs
BIOA
$1.01B
$875K 0.35%
50,000
+5,000
+11% +$96.3K
CNTB
44
Connect Biopharma Holdings
CNTB
$150M
$812K 0.33%
+310,000
New +$808K
HRTX icon
45
CALL
Heron Therapeutics
HRTX
$89.1M
$800K 0.32%
+1,000,000
New +$1.16M
RADX
46
Radiopharm Theranostics
RADX
$34.9M
$739K 0.3%
51,000,000
– –
MXCT icon
47
MaxCyte
MXCT
$133M
$706K 0.28%
1,004,673
+535,655
+114% +$500K
CDXS icon
48
Codexis
CDXS
$204M
$681K 0.27%
417,994
+161,888
+63% +$231K
BOLD
49
Boundless Bio
BOLD
$55.7M
$657K 0.26%
597,682
-112,389
-16% -$131K
HELP
50
Cybin Inc
HELP
$449M
$643K 0.26%
134,060
-205,842
-61% -$1.33M
1
2
3 4

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Stonepine Capital Management held 100 positions worth $250M, up 82% from $137M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Stonepine Capital Management deployed $139M of net new capital in Q1 2026, opening 34 new positions and adding to 19 existing holdings. Its largest new stake was Sol-Gel Technologies: 27,778 shares worth $2.2M.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Inhibikase Therapeutics, an estimated $2.47M trimmed.

  • Stonepine Capital Management's largest Q1 2026 buy was Sol-Gel Technologies: 27,778 shares worth $2.2M.
  • Stonepine Capital Management added most to Tenax Therapeutics in Q1 2026, an estimated $13M increase.
  • Stonepine Capital Management's biggest Q1 2026 reduction was Inhibikase Therapeutics, cutting an estimated $2.47M.
  • Stonepine Capital Management fully exited Indivior Pharmaceuticals in Q1 2026, selling an estimated $3.59M.
  • Stonepine Capital Management's ten largest holdings make up 71% of its $250M portfolio in Q1 2026.
  • Stonepine Capital Management opened 34 new positions and closed 17 in Q1 2026.
  • Stonepine Capital Management's portfolio value rose 82% quarter-over-quarter to $250M.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.